Compare EDUC & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | GDTC |
|---|---|---|
| Founded | 1965 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 12.4M |
| IPO Year | 1995 | 2021 |
| Metric | EDUC | GDTC |
|---|---|---|
| Price | $1.32 | $1.06 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 19.2K | 13.0K |
| Earning Date | 01-08-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $34,191,000.00 | N/A |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.11 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.92 | $0.73 |
| 52 Week High | $1.84 | $3.68 |
| Indicator | EDUC | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 44.39 | 50.87 |
| Support Level | $1.25 | $0.96 |
| Resistance Level | $1.35 | $1.11 |
| Average True Range (ATR) | 0.05 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 28.00 | 65.71 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.